Sahm ScreenerSaudi Stock Screenerفلتر الأسهم السعودية
Home / Jamjoom Pharmaceuticals Factory Co. / 2023 Annual Results

Jamjoom Pharmaceuticals Factory Co. 2023 Annual Results

Revenue
SAR 1.10B
Net Profit
SAR 292M
EPS
SAR 4.18
Operating Cash Flow
SAR 296M

Jamjoom Pharmaceuticals Factory Co. (4015) reported full year 2023 revenue of SAR 1.10B, up 241.1% from SAR 323M in 2022. Net profit came in at SAR 292M, up 70.7% year on year. Earnings per share were SAR 4.18. The company generated SAR 296M in operating cash flow. All figures sourced from CMA-mandated XBRL filings on the Saudi Exchange, processed by Sahm Screener.

Earnings Quality

Of every SAR 1.00 in reported net profit, SAR 1.01 arrived as operating cash flow — indicating Exceptional quality earnings with a cash conversion ratio of 1.01.

Key Financial Metrics

Metric20232022
RevenueSAR 1.10BSAR 323M
Net ProfitSAR 292MSAR 171M
Gross ProfitSAR 594M
Net Margin26.6%53.1%
ROE20.8%14.1%
EPSSAR 4.18
Total AssetsSAR 1.65BSAR 1.41B
Total EquitySAR 1.40BSAR 1.22B
Total LiabilitiesSAR 250M
Operating Cash FlowSAR 296M

Year on Year Comparison

Revenue increased by 241.1% compared to 2022. Net profit increased by 70.7%. Both revenue and profit grew — indicating expanding business.

View full company profile →
View all years:
2025202420232022202120202019

Financial data sourced from CMA-mandated XBRL filings published on the Saudi Exchange (Tadawul). Data processed and structured by Sahm Screener (sahmscreener.com). Updated nightly. Last updated: 2024-04-01.